Search





Search





CORRECTED-Immunovant's treatment for eye disease fails late-stage trials

ReutersApr 2, 2026 9:22 AM

April 2 (Reuters) - Immunovant IMVT.O said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in two late-stage studies.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

WTI Oil Price Forecast: Trump Personally Opened the Path to Above $120.00

TradingKey - WTI prices continued to surge today as the market reprices Middle East risk.

Trump National Address ‘About-Face,’ Bitcoin Slumps Back to $66,000

Trump’s major reversal on Iran sparked a nearly 3% drop in Bitcoin, with the upcoming non-farm payroll data becoming a key focus.

SpaceX Reported to File for IPO—Here Is Another Reason to Buy Amazon Stock

TradingKey - According to a report on Reuters, SpaceX has confidentially submitted an IPO to be the largest since the original record of $25 billion. SpaceX IPO would create another publicly traded company that focuses solely on providing customers with high-speed internet through the use of satelli

Amazon Talks to Acquire Globalstar: Can $9 Billion Deal Challenge SpaceX Starlink?

TradingKey - During after-hours trading on April 1, 2026, shares of satellite communications company Globalstar (GSAT) surged 24%, with its market capitalization briefly approaching $9 billion. The rally was triggered by an exclusive report from the Financial Times stating that e-commerce giant Amaz

Bitcoin Price Analysis: What Is to Stop BTC from Making Another Run at All-Time Highs in 2026?

This strategic analysis covers institutional BTC price targets from JPMorgan and Fidelity, the impact of the U.S. Strategic Reserve, and whether the four-year cycle is broken. Stay updated on BTC to USD trends and key market risks.

Tradingkey

KeyAI

